Carbogen Amcis enters into a co-investment agreement of CHF 25+ million to expand Swiss sites

This project builds on a previous joint funding agreement between CARBOGEN AMCIS and the same customer in April 2021

Novartis to invest $23 billion on expansion of manufacturing and R&D facilities in US

Expanded US manufacturing and R&D presence with investment in 10 facilities, including 7 brand new facilities

Granules India completes acquisition of Senn Chemicals

Strengthening capabilities in Peptide Therapeutics and CDMO services

Amcor's Bloom Biorenewables secures $14 million Series A Funding

Bloom has pioneered a technology to transform plant waste into valuable chemical products

Indegene launches new center in London

Carbogen Amcis appoints Stephan Fritschi as CEO

Pascal Villemagne has announced his intent to step down at the end of March 2025, to take on a new challenge in his professional career.

Calquence combination approved in US for untreated mantle cell lymphoma

Based on ECHO Phase III trial results which showed more than 16 months of progression-free survival improvement vs. chemoimmunotherapy alone

Carbogen Amcis successfully completed Swissmedic inspection of its Vionnaz facility

The site’s GMP Certification has been successfully renewed

Gilead Sciences appoints Dietmar Berger as Chief Medical Officer

Dr. Berger is a board-certified internist, hematologist and oncologist who brings more than 25 years of extensive experience in developing and delivering innovative medicines

USFDA accepts Blenrep combinations for treatment of relapsed/refractory multiple myeloma

If approved, Blenrep (belantamab mafodotin) in combinations with BorDex (BVd) and PomDex (BPd) could redefine multiple myeloma treatment at or after first relapse